韓國用晶片換疫苗的新聞:

Samsung to leverage chip investment for 'vaccine swap'
https://www.koreatimes.co.kr/www/te...693_308869.html

節錄幾段:
Samsung Group, the sprawling South Korean business conglomerate, is being highlighted ahead of President Moon Jae-in's first-ever summit with U.S. President Joe Biden at the White House on May 21. Samsung's biotechnology affiliate is set to reach a "vaccine swap" in return for the conglomerate's semiconductor unit investing billions of dollars to boost memory chip production in the United States.

More specifically, Lee Ho-seung, the President's chief policy secretary, said the U.S. has a strong interest in turning South Korea into a global vaccine production hub. Lee explained that the plan makes sense, since the U.S. possesses vaccine patents and raw materials, while South Korea possesses the world's second-highest drug manufacturing capacity.

"Samsung Biologics could play a greater role as it already produces vaccines at its manufacturing plants in South Korea on a contractual basis. What Samsung wants is to acquire some patented technology not just to win vaccine production orders from Pfizer and Moderna, but to expand its supply lines in Asia and Europe," a senior executive said by telephone...

So far, the U.S. has shown reluctance in sharing some of the patented biopharmaceutical technologies of its bio companies, since they are considered "strategic items," according to sources.

Samsung officials declined to comment. But sources said its planned memory chip investment in the U.S., estimated to be as high as $20 billion, could assuage concerns about inking a "technology partnership" over COVID-19 vaccines.

標題說是 以 '晶片' 換 '疫苗'... 但內文其實是以 '三星半導體在美國投資' 換 '生產疫苗的專利技術'. 美國也想獲得 晶片 這種戰略物資.

重點:

韓國希望能取得 Covid-19 疫苗 (Pfizer 和 Moderna) 的專利技術, 以便 生產/代工 疫苗, 和 供給/輸出 到亞洲和歐洲.
韓國目前有藥物生產的實力為全球第二.
三星在美國投資金額將高達 200 億美金.

在南韓, 三星 和 政府的關係 應該跟在台灣, 台積電 和 政府的關係 不一樣吧?